Michael Nally - 26 Feb 2026 Form 4 Insider Report for Generate Biomedicines, Inc. (GENB)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: GENB
Reported as of: 26 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Mar 2026, 17:50:58 UTC
Prior SEC filing: 15 Dec 2025
Next SEC filing: 06 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael Wolf, Attorney-in-Fact

Key filing fact

Michael Nally filed Form 4 for Generate Biomedicines, Inc. (GENB) on 02 Mar 2026.

Key facts

This page summarizes Michael Nally's Form 4 filing for Generate Biomedicines, Inc. (GENB).
4 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 02 Mar 2026, 17:50.

Change

Previous filing in this sequence was filed on 15 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001763945 Primary reporting owner

Nally Michael

Relationship: Chief Executive Officer, Director
Address: GENERATE BIOMEDICINES, INC., 101 SOUTH STREET, SUITE 900, SOMERVILLE
Signature: /s/ Michael Wolf, Attorney-in-Fact
Signature date: 02 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GENB transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +658,327
Change %: +100%
Price
Shares after: 1,316,654
Date: 02 Mar 2026
Ownership: By MTN 2024 GST Trust
Footnotes: F1, F2

GENB holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 552,707
Date: 26 Feb 2026
Ownership: Direct

GENB holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 999,793
Date: 26 Feb 2026
Ownership: By MTN 2024 GRAT
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GENB transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +844,595
Change %
Price: $0.000000
Shares after: 844,595
Date: 26 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 844,595
Exercise price: $16.00
Footnotes: F3

GENB transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +844,595
Change %
Price: $0.000000
Shares after: 844,595
Date: 26 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 844,595
Exercise price: $16.00
Footnotes: F4

GENB transaction Derivative

Series A Preferred Stock

Conversion of derivative security

Transaction value: $0
Shares: -1,000,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 02 Mar 2026
Ownership: By MTN 2024 GST Trust
Underlying class: Common Stock
Underlying amount: 658,327
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Each share of Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Series A Preferred Stock had no expiration date.

Footnote F2

The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Footnote F3

The shares underlying this option shall vest in two equal installments on each of February 19, 2029 and February 19, 2030, subject to the Reporting Person's continued service on each such vesting date.

Footnote F4

The shares underlying this option shall vest in forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date.